Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 401–500 of 678

Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Liu, Y., Yu, C., Yang, J. C., & Shih, J. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22647 · Cited by 18
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
Kim, T., Han, S., & Bang, Y. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.6.821 · Cited by 16
HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas
Reis, H., Herold, T., Ting, S. C., Worm, K., Huber, U., Christoph, D. C., Eberhardt, W., Kostbade, K., Kasper, S., Stamatis, G., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.002 · Cited by 16
Parameters for individualizing systemic therapy in non-small cell lung cancer
Gadgeel, S. M., Coté, M. L., Schwartz, A. G., Matherly, L. H., Wozniak, A. J., & Bepler, G. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.10.001 · Cited by 17
From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer
Dimou, A., Harrington, K. J., & Syrigos, K. (2011) · Pathology Research International · doi:10.4061/2011/312346 · Cited by 16
Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
Wang, L., Cui, J., Guo, A.-X., & Yin, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s136579 · Cited by 16
Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)
Yang, G., Hao, X., Hu, J., Dong, K., Xu, H., Yang, L., Zhang, S., Yang, Y., Xu, F., Li, J., et al. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.08.001 · Cited by 15
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Zhou, F., & Zhou, C. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0036-4 · Cited by 17
Key Signaling Pathways and Targets in Lung Cancer Therapy
Choong, N. W., Salgia, R., & Vokes, E. E. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.s.002 · Cited by 16
Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines
Regan, E., Sibley, R. C., Cenik, B. K., Silva, A., Girard, L., Minna, J. D., & Dellinger, M. T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150963 · Cited by 16
Self-citation
Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis
Đačić, S. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.77 · Cited by 16
Lung cancer as a paradigm for precision oncology in solid tumours
Schallenberg, S., Merkelbach‐Bruse, S., & Buettner, R. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2183-2 · Cited by 17
Evaluation of HER2 in breast cancer: reality and expectations
Milanezi, F., Leitão, D., Ricardo, S. A. V., Augusto, I., & Schmitt, F. C. (2009) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050903222221 · Cited by 15
Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
Shi, Y., & Wang, M. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12906 · Cited by 15
Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP‐412 (AV‐412) in mouse xenograft models
Suzuki, T., Fujii, A., Ohya, J., Nakamura, H., Fujita, F., Koike, M., & Fujita, M. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01197.x · Cited by 15
Pulmonary Adenocarcinoma In Situ
Sato, S., Motoi, N., Hiramatsu, M., Miyauchi, E., Ono, H., Saito, Y., Nagano, H., Ninomiya, H., Inamura, K., Uehara, H., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000458 · Cited by 15
SUCI02 inhibits the erbB‐2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells
Zhu, X., Wang, J., Cai, L., Zeng, Y., & Yang, D. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2006.00143.x · Cited by 15
High-Throughput Mutational Analysis of the Human Cancer Genome
Ma, P. C., Zhang, X., & Wang, Z. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.4.597 · Cited by 15
Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
Dancey, J. E. (2007) · Drugs · doi:10.2165/00003495-200767080-00003 · Cited by 15
A practical and adaptive approach to lung cancer screening: a review of international evidence and position on CT lung cancer screening in the Singaporean population by the College of Radiologists Singapore
Liew, C., Leong, L., Teo, L., Ong, C., Fk, C., Tham, W., Mohamed, H. M. S., Lee, C. H., Kaw, G. J. L., Tee, A., et al. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019145 · Cited by 14
The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer
Chen, L., Yang, J., Zheng, M., Kong, X., Huang, T., & Cai, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128696 · Cited by 14
The breast cancer susceptibility FGFR2 provides an alternate mode of HER2 activation
Wei, W., Liu, W., Serra, S., Asa, S. L., & Ezzat, S. (2015) · Oncogene · doi:10.1038/onc.2014.440 · Cited by 16
Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype
Telesco, S., Vadigepalli, R., & Radhakrishnan, R. (2013) · Biotechnology Journal · doi:10.1002/biot.201300022 · Cited by 14
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA
Chang, L., Chiu, H., Shun, C., Liang, J., Lin, J., Chen, C.-C., Lee, Y., & Wu, M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0221-y · Cited by 14
Molecular Testing of Non–Small Cell Lung Carcinoma Biopsy and Cytology Specimens
Wistuba, I. I. (2012) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2012.32.44 · Cited by 14
Self-citation
Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer
Ko, Y. S., Kim, N. Y., & Pyo, J. (2017) · The International Journal of Biological Markers · doi:10.5301/ijbm.5000271 · Cited by 14
EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Non–Small Cell Lung Cancer
Miller, V. A. (2008) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2007.11.009 · Cited by 13
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 15
Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
Yang, G., Xu, H., Hu, J., Liu, R., Hu, P., Yang, Y., Li, W., Hao, X., Zhang, S., Xu, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806737 · Cited by 13
Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
Han, Y., Xiong, Y., Lu, T., Chen, R., Liu, Y., Tang, H. J., Geng, R., & Wang, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121708 · Cited by 13
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma
Hutchinson, K. E., Johnson, D. B., Johnson, A. S., Sanchez, V. M., Kuba, M. G., Wang, L., Chen, X., Kelley, M. C., Wang, Q., Zhao, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4255 · Cited by 13
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
Ai, X., Song, Z., Jian, H., Zhou, Z., Chen, Z., Yu, Y., Li, Z., & Lü, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08759-8 · Cited by 13
Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Shukla, S., Khan, S. U., Tollefsbol, T. O., & Meeran, S. M. (2013) · Current Cancer Therapy Reviews · doi:10.2174/15733947113099990002 · Cited by 14
Molecular Carcinogenesis
Zachariadis, M., Evangelou, K., Kastrinakis, N. G., Papanagnou, P., & Gorgoulis, V. G. (2010) · Springer eBooks · doi:10.1007/978-3-540-71915-1_74 · Cited by 13
Inducible and Transmissible Genetic Events and Pediatric Tumors of the Nervous System
Rice, J. M. (2006) · Journal of Radiation Research · doi:10.1269/jrr.47.b1 · Cited by 13
Awareness and Attitudes about Disease Mongering among Medical and Pharmaceutical Students
Kumar, C., Deoker, A., Kumar, A., Kumar, A., & Hegde, B. M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030213 · Cited by 13
Targeted Therapies for Non-Small Cell Lung Cancer
Παπαέτης, Γ., Roussos, C., & Syrigos, K. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781757079 · Cited by 13
A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
Amisha, F., Malik, P., Saluja, P., Gautam, N., Patel, T. H., Roy, A. M., Singh, S. R. K., & Malapati, S. J. (2023) · Onco · doi:10.3390/onco3020008 · Cited by 13
Respiratory Tract and Mediastinum
French, C. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4462-6.00002-7 · Cited by 12
Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology
Holden, J. A., Willmore‐Payne, C., & Layfield, L. J. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.03.010 · Cited by 12
Targeting novel and established therapies for non-small cell lung cancer
Spicer, J. F., Chowdhury, S., & Harper, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.09.001 · Cited by 11
Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
Krawczyk, P. A., Mlak, R., Powrózek, T., Nicoś, M., Kowalski, D. M., Wojas‐Krawczyk, K., & Milanowski, J. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.31768 · Cited by 10
Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors
Kotteas, E. A., Charpidou, A. G., & Syrigos, K. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328334da02 · Cited by 11
Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout
Favoni, R. E., & Alama, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.011 · Cited by 11
Going beyond EGFR
Zimmermann, S., & Peters, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds319 · Cited by 11
Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method
Takase, Y., Usui, K., Shimizu, K., Kimura, Y., Ichihara, T., Takahiro, O., Atsumi, J., Enokida, Y., Nakazawa, S., Obayashi, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171225 · Cited by 11
Identification of a Water-Coordinating HER2 Inhibitor by Virtual Screening Using Similarity-Based Scoring
Guo, J., Collins, S. J., Miller, W. T., & Rizzo, R. C. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00524 · Cited by 11
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants
Fan, Y., Wong, L., Marino, M. P., Ou, W., Shen, Y., Wu, W. J., Wong, K., Reiser, J., & Johnson, G. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434217 · Cited by 11
Direct resequencing of the completeERBB2coding sequence reveals an absence of activating mutations inERBB2amplified breast cancer
Zito, C. I., Riches, D., Kolmakova, J., Simons, J. F., Egholm, M., & Stern, D. F. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20566 · Cited by 11
Cancer bronchique de la femme et de la femme enceinte : vers une origine hormonale ?
Mazières, J., Rouquette, I., & Brouchet, L. (2007) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(07)92763-1 · Cited by 13
Molecular Alterations in Lung Adenocarcinoma With Ground-Glass Nodules: A Systematic Review and Meta-Analysis
Wei, Z., Wang, Z., Nie, Y., Zhang, K., Shen, H., Wang, X., Wu, M., Yang, F., & Chen, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724692 · Cited by 10
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
Yagui‐Beltrán, A., & Jablons, D. M. (2009) · PubMed · Cited by 10
The EGFR/ERBB Receptor Family
Pareja, F. G., Pines, G., & Yarden, Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_4 · Cited by 9
A systematic analysis of the resistance and sensitivity of HER2YVMAreceptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer
Shen, X., Chen, B., Ma, Z., Xie, B., Cao, X., Yang, T., Zhao, Y., Qin, J., Li, J., Cao, F., et al. (2015) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2015.1049361 · Cited by 10
Advancing Personalized Cancer Medicine in Lung Cancer
MacConaill, L. E. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0244-sa · Cited by 10
Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation
Wang, J., Wen, Y., Ding, G., Ding, P., Zhang, L., Liu, J., Zhang, T., & Yang, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449611 · Cited by 10
Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer
Hashim, M., Sayed, M., Samy, N., & Elshazly, S. (2010) · Medical Oncology · doi:10.1007/s12032-010-9444-0 · Cited by 10
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers
Tian, X., Esmaeili, H. A., Minich, D., Seitz, F., Roessner, P. M., Wind, S., Grempler, R., Gan, G., Chan, T. S., Mahmoudi, M., et al. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4641 · Cited by 9
Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development
Wijesinghe, P., & Bollig-Fischer, A. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_1 · Cited by 9
Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer
Chawla, P. A., Billowria, K., & Gupta, G. D. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220523145609 · Cited by 9
Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2020035 · Cited by 9
Molecular Basis of Pulmonary Disease
Farver, C. F., & Zander, D. S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00018-4 · Cited by 10
HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib
Xu, J., Shen, L., Zhang, B., Xu, W., Ruan, S.-Q., Pan, C., & Wei, Q. (2016) · Oncology Letters · doi:10.3892/ol.2016.5373 · Cited by 9
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Velázquez, A. I., & McCoach, C. E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.31 · Cited by 9
Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Cappuzzo, F. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268634.17956.5e · Cited by 9
[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].
Liu, H., Wang, M., Hu, K., Xu, Y., Ma, M., Zhong, W., Zhao, J., Li, L., & Wang, H. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.10.07 · Cited by 9
Targeting ERBB Receptors in Cancer
Hynes, N. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_4 · Cited by 9
Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients
Ricarte‐Filho, J. C., Matsuse, M., Lau, C., Ryder, M. M., Nishihara, E., Ghossein, R. A., Ladanyi, M., Yamashita, S., Mitsutake, N., & Fagin, J. A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26267 · Cited by 9
Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
Shan, J., Ruan, J., Tan, Y., Li, Y., Chen, S., Du, M., & Wang, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s271999 · Cited by 8
Pyrotinib plus antiangiogenic agents for HER2 ‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
Yang, Y., Yang, G., Li, W., Hao, X., Zhang, S., Ai, X., Lei, S., Xu, H., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15118 · Cited by 8
Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report
Gao, Y., Zheng, A.-H., Zhu, X., Song, J., & Xue, Q. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182812 · Cited by 8
Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma
Mehta, A., Nathany, S., Tripathi, R., Sharma, S. K., Saifi, M., & Batra, U. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206730 · Cited by 8
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
Xu, H., Qi, L., Xu, X., Tan, S., Wang, S., Liu, Y., & Liu, L. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02444-7 · Cited by 7
ERBB2 Amplification in NSCLC: How Many Faces?
Shih, J. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.02.001 · Cited by 7
Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study
Yang, G., Liu, R., Li, P., Yang, Y., Wang, Y., Mao, H., & Tang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01154-2 · Cited by 7
Mecanismo de acción y desarrollo preclínico de afatinib
Taín, P. D., González, A. L., & Palomo, A. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30257-3 · Cited by 7
Perspective Chapter: Molecular Pathology of Lung Cancer
Gandhi, S. J., Gupta, I., Menia, R., & Kumar, R. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109598 · Cited by 7
Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
Tanaka, H., Ueda, K., Karita, M., Ono, T., Manabe, Y., Kajima, M., Fujimoto, K., Yuasa, Y., & Shiinoki, T. (2023) · Cancers · doi:10.3390/cancers15174260 · Cited by 7
Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways
de Sousa, V. M. L., Lopes-Bastos, B., Silva, M. M. P., Alarcão, A., & Carvalho, L. (2015) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2014.05.006 · Cited by 7
Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.
Telesco, S., Shih, A., Liu, Y., & Radhakrishnan, R. (2011) · PubMed · Cited by 7
HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma
Jia, Z., Xing, J., Li, J., Wang, W., Wang, Y., Song, Y., Yang, X., Xue, J., Ye, J., Li, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-107 · Cited by 7
Ado-trastuzumab emtansine in the treatment of lung adenocarcinoma with ERBB2 mutation: a case report and literature review
Wang, H., He, Y., Zhao, W., & Tong, Z. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001369 · Cited by 7
Epidermal growth factor receptor pathway inhibitors
Baselga, J. M. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.08.002 · Cited by 7
The significance of plasma high density lipoprotein cholesterol (hdlc).
Gupta, S., & Rajagopal, G. (2007) · PubMed · Cited by 7
Molecular Biology of Lung Preneoplasia
Kadara, H. N., & Wistuba, I. I. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch6 · Cited by 7
Self-citation
Epidermal Growth Factor Receptor Family
Tvorogov, D., & Carpenter, G. F. (2004) · Encyclopedia of Biological Chemistry · doi:10.1016/b0-12-443710-9/00206-4 · Cited by 7
Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer
Huang, Y., Zhao, Y., Huang, Y., Yang, Y., Zhang, Y., Hong, S., Zhao, H., Zhao, S., Zhou, T., Chen, G., et al. (2024) · MedComm · doi:10.1002/mco2.536 · Cited by 6
Molecular recognition of tak-285 and lapatinib by inactive, active, and middle active-inactive HER2
Bello, M. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04720-5 · Cited by 6
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
Vari, S., Pilotto, S., Maugeri‐Saccà, M., Ciuffreda, L., Incani, U. C., Falcone, I., Curatolo, A. D., Ceribelli, A., Gelibter, A. J., Maria, R. D., et al. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.843523 · Cited by 6
Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system
Krawczyk, P. A., Nicoś, M., Powrózek, T., Mlak, R., Sawicki, M., Jarosz, B., Pająk, B., Kucharczyk, K., Stencel, D. M., Trojanowski, T., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1495 · Cited by 6
Le tabac et ses conséquences dans le cadre du traitement du cancer bronchique
Rivera, C., Rivera, S., Fabre, E., Pricopi, C., Pimpec‐Barthes, F. L., & Riquet, M. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2014.11.009 · Cited by 6
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib‐treated NSCLC PC‐9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy
Yuan, Y., Liu, L., Wang, Y., & Liu, S. (2020) · Cell Biology International · doi:10.1002/cbin.11397 · Cited by 6
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Koivu, M. K. A., Chakroborty, D., Tamirat, M. Z., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0590 · Cited by 5
The place of targeted therapies in the management of non-small cell bronchial carcinoma
Rosell, R., Morán, T., Salazar, M., Méndez, P., de Aguirre, I., Ramírez, J. L., Isla, D., Cobo, M., Camps, C., López-Vivanco, G., et al. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)72061-7 · Cited by 6
Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges
Cappuzzo, F., Toschi, L., Finocchiaro, G., Ligorio, C., & Santoro, A. (2007) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.5699 · Cited by 7
The Need for an Individual Approach to Lung Cancer Treatment
Shigematsu, H., Toyooka, S., & Suzuki, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030206 · Cited by 6
Self-citation
A Perspective Analysis: Companion Diagnostics: An Evolving Paradigm in 21st Century Healthcare
Kaufmann, M., Keppens, M., & Blair, E. D. (2015) · Personalized Medicine · doi:10.2217/pme.15.2 · Cited by 5

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks